MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Losartan (Cozaar®)

Selected References:

  • Alwan S, et al. 2005. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol. 73:123-130.
  • Bass JK, Faix RG. 2006. Gestational Therapy with an Angiotensin II Receptor Antagonist and Transient Renal Failure in a Premature Infant. Am J Perinatol. 23:313-318.
  • Centers for Disease Control and Prevention. 2020. Facts about craniosynostosis. Centers for Disease Control and Prevention. Available oneline at https ://www.cdc.gov/ncbddd/birthdefects/craniosynostosis.html. [Accessed Jan 2023].
  • Daikha-Dahmane F, et al. 2006. Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol. 21(5):729-32.
  • Diav-Citrin O, et al. 2011. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol. 31(4):540-545.
  • Gersak K, et al. 2009. Angiotensin II receptor blockers in pregnancy: a report of 5 cases. Reprod Toxicol. 28(1):109-12.
  • Lambot M, et al. 2001. Angiotensin-II-receptor inhibitors in pregnancy. Lancet. 357:1619-1620.
  • Marin EC, et al. 2014. The role of oxidative stress in renal injury induced in rats by losartan exposure during lactation. J Renin Angiotensin Aldosterone Syst. 15(4): 362-377.
  • Martinovic J, et al. 2001. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet. 358:241-242.
  • Saji H, et al. 2001. Losartan and fetal toxic effects. Lancet. 357:363.
  • Schaefer C. 2003. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res Part A Clin Mol Teratol. 67:591-594.
  • Sergesketter AR, et al. 2019. Characterization of Perinatal Risk Factors and Complications Associated with Nonsyndromic Craniosynostosis. J Craniofac Surg; 30(2):334-338.
  • Serreau R, et al. 2005. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. BJOG. 112(6):710-712.
  • Sica DA, et al. 2005. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 44(8):797-814.
  • Spaggiari E, et al. 2012. Renin-Angiotensin System Blockers Study Group, Muller F. Prognosis and outcome of pregnancies exposed to renin-angiotensin system blockers. Prenat Diagn. 18:1-6.
  • Spence SG, et al. 1995. Evaluation of the reproductive and developmental toxicity of the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology. 51:383-97.
  • Stevenson KM, et al. 1996. Effects of losartan on the cardiovascular system, renal haemodynamics and function and lung liquid flow in fetal sheep. Clin Exp Pharmacol Physiol. 23:125-33.
  • Wei Q, et al. 2021. Use of angiotensin II receptor blocker during pregnancy: A case report. Medicine (Baltimore). 22;100(3):e24304.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.